Tumor Milieu Controlled by RB Tumor Suppressor

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The RB gene is frequently mutated in human cancers, traditionally linked to cell cycle regulation.
• RB gene aberrations often correlate with aggressive cancer phenotypes like metastasis and drug resistance, suggesting cell cycle-independent roles.
• RB protein's functions extend beyond cell cycle control, influencing tumor lineage plasticity, metabolism, and the tumor microenvironment (TME).

Purpose of the Study:

• To review the multifaceted functions of the RB protein.
• To focus on RB's role in controlling the tumor microenvironment (TME).
• To discuss the non-cell-autonomous functions of RB and their clinical relevance to cancer immunotherapy.

Main Methods:

• Literature review focusing on RB gene functions in cancer.
• Analysis of RB's role in tumor lineage plasticity, metabolism, and TME.
• Examination of RB's impact on cytokine production and reactive oxygen species (ROS).

Main Results:

• RB inactivation enhances pro-inflammatory cytokine production (e.g., CCL2) via mitochondrial ROS.
• RB inactivation promotes both cell-autonomous cancer growth and non-cell-autonomous TME reprogramming.
• RB's non-cell-autonomous functions contribute to a pro-tumorigenic niche.

Conclusions:

• RB plays a critical role in regulating the TME through non-cell-autonomous mechanisms.
• RB inactivation drives cancer aggressiveness by modulating inflammation and the TME.
• Understanding RB's non-cell-autonomous functions may offer new avenues for cancer immunotherapy.